{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:48:13Z","timestamp":1788994093689,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives\/Background<\/jats:title>\n                    <jats:p>To explore the safety and effectiveness of using two preventive calcitonin gene\u2010related peptide (CGRP) antagonists in patients with chronic migraine. Although the literature supports concurrent use of CGRP antagonists for acute and preventive treatment of chronic migraine, it is unknown whether two concurrent preventive CGRP agents are safe and effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with chronic migraine who were prescribed two preventive CGRP antagonists, one monoclonal antibody (e.g., eptinezumab, erenumab, fremanezumab, galcanezumab) and one oral agent (gepant) (e.g., atogepant, rimegepant) were included in this retrospective cohort study. Patients served as their own controls in a pre\u2013post analysis completed at the University of Vermont Health Network, including data from January 1, 2020 through December 31, 2024. Demographic, clinical, and medication data were recorded at baseline (immediately prior to the addition of a second CGRP antagonist) and after a minimum of 3\u2009months of dual therapy. The primary outcome was the change in patient\u2010reported headache in days per month. Secondary outcomes included changes in severe headache or migraine in days per month, adverse events, and the rate and reasons for discontinuation of dual preventive therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 37 patients who were included, the average age was 54\u2009years, and the population was primarily female (86%), White (94%), and commercially insured (57%). There was a significant decrease in headache days (median\u2009=\u20090; interquartile range = \u22125 to 0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.031) while on two CGRP antagonists, including 8 patients (22%) who achieved at least a 50% reduction in reported headache days. There was also a significant reduction in severe headache or migraine days (median\u2009=\u2009\u22122; interquartile range = \u22126 to 0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). There was no significant increase in adverse events with two CGRP antagonists (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.219 sign test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.103 McNemar test). However, a single case of ischemic stroke was reported in a patient with multiple risk factors. Half of all patients (19, 51%) discontinued at least one CGRP antagonist by the end of the study period, primarily due to insurance restrictions or lack of perceived benefit. No patients discontinued due to reported side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Trialing two preventive CGRP antagonists may be an effective approach for some patients with chronic migraine who have exhausted other preventive treatment options, with some patients in this study experiencing a significant reduction in headache frequency and severity. Prospective studies with larger, more diverse populations should be completed to confirm these findings and investigate any potential stroke risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.70057","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T03:55:28Z","timestamp":1770954928000},"page":"1099-1107","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating dual calcitonin gene\u2010related peptide antagonists for chronic migraine prevention"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3448-7485","authenticated-orcid":false,"given":"Kara S.","family":"Graves","sequence":"first","affiliation":[{"name":"University of Vermont Medical Center  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4927-1795","authenticated-orcid":false,"given":"Jason","family":"To","sequence":"additional","affiliation":[{"name":"University of Vermont Medical Center  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Paige","sequence":"additional","affiliation":[{"name":"Maine Health  Portland Maine USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-4961","authenticated-orcid":false,"given":"Amanda G.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"University of Vermont Larner College of Medicine  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-707X","authenticated-orcid":false,"given":"Adam S.","family":"Sprouse\u2010Blum","sequence":"additional","affiliation":[{"name":"University of Vermont Larner College of Medicine  Burlington Vermont USA"},{"name":"University of Vermont  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3542-037X","authenticated-orcid":false,"given":"Derek","family":"Devine","sequence":"additional","affiliation":[{"name":"Biomedical Statistics Research Core University of Vermont  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4087-2853","authenticated-orcid":false,"given":"Julie","family":"MacDougall","sequence":"additional","affiliation":[{"name":"University of Vermont Medical Center  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14709"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.315972"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00409-9"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-47"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2417655"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16322"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00586-w"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01709.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1130239"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008944"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14095"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13930"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00556-8"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14871"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14051"},{"key":"e_1_2_11_19_1","volume-title":"AIMOVIG (Erenumab Aooe) [Prescribing Information]","year":"2025"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1257282"},{"issue":"1","key":"e_1_2_11_21_1","first-page":"1","article-title":"Disproportionality analysis of Raynaud's phenomenon associated with calcitonin gene\u2010related peptide inhibitors using the Food and Drug Administration adverse event reporting system","volume":"15","author":"Lee N","year":"2025","journal-title":"Sci Rep"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213852"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312233"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.2.308"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1090878"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X18800589"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05592-3"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.576967"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.70057","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:42:30Z","timestamp":1786632150000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.70057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/head.70057"],"URL":"https:\/\/doi.org\/10.1111\/head.70057","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"2025-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}